Nebulized glycopyrrolate improves lung function in COPD patients


eMediNexus    02 November 2017

Nebulized glycopyrrolate was well tolerated and improved lung function and patient reported outcomes with an acceptable safety and tolerability profile in COPD patients with and without background LABA ICS for up to 48 weeks according to the GOLDEN Phase 3 studies presented October 31 2017 at Chest annual meeting in Toronto. The study suggests it as a new treatment option for patients who may require or benefit from nebulized long acting muscarinic antagonist LAMA therapy.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.